At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

In chronic myeloid leukemia, combining asciminib with a tyrosine kinase inhibitor shows increasing efficacy and tolerability over 3 years.

Terns Pharmaceuticals, Inc. ( TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia December 8, 2025 4:30 PM EST ...

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety ...

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety ...

Orca Bio presents positive new data from its pipeline of allogeneic T-cell immunotherapies at the 67th ASH Annual Meeting.

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...

Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients ...

The US Acute Myeloid Leukemia Market is poised for continued growth, expected to show a CAGR of $% from 2022 to 2028. The future outlook is characterized by: The ongoing development of targeted ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

ASH will recognize Rainer Storb, MD, with the Wallace H. Coulter Award for Lifetime Achievement in Hematology, the society's highest honor. See below for summaries and links to selected Fred Hutch ...